Monday, July 18, 2016
BioPlus now dispensing Gilead’s Epclusa
ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy announced this week that it is now dispensing Gilead’s recently approved Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg).
The drug, which combines Gilead’s Sovaldi (sofosbuvir) with an NS5A inhibitor called velpatasvir, is indicated to treat all six strains of hepatitis C.
“One of the exciting things for prescribers and patients about Epclusa is that it’s approved to treat all six genotypes,” BioPlus VP pharmaceutical relations Sharon Ferrer said. “In addition, the low cost (wholesale acquisition cost of $74,760) comes in at nearly 50% lower than previous treatments available for the difficult-to-treat genotype 3 of hepatitis C virus.”